Loading...
•
Sep 30, 2021
Lineage Q3 2021 Earnings Report
Reported financial and operating results, highlighting progress from clinical cell therapy programs.
Key Takeaways
Lineage Cell Therapeutics reported a net loss of $7.8 million, or $0.05 per share, for the third quarter of 2021. Total revenues were $2.3 million, an increase of $1.7 million compared to the same period in 2020. Cash, cash equivalents, and marketable securities totaled $65.1 million as of September 30, 2021.
Reported positive interim outcomes in patients with dry AMD with geographic atrophy.
Initiated performance testing of OPC1 delivery device for spinal cord injury.
Expanded executive team with the appointment of a new General Counsel.
Preparing for engagement with FDA for OpRegen program to discuss aspects of product designation, manufacturing plans, and later-stage clinical development.
Forward Guidance
Lineage is preparing for engagement with FDA for its OpRegen program and looks forward to the initiation of its OPC1 and novel delivery device clinical safety study early next year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...